AK Medical Holdings Ltd (1789) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of AK Medical Holdings Ltd stock HK$7.71, price HK$4.76, upside +62.1%, quality 73 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range HK$3.39 – HK$13.70 · fair‑value band HK$4.72 – HK$10.68 · the HK$4.76 price screens below the HK$7.71 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow AK Medical Holdings in your weekly email
Every Wednesday you see whether AK Medical Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
AK Medical Holdings Limited, an investment holding company, designs, develops, produces, and markets orthopedic joint implants and related products in the People's Republic of China, the United Kingdom, and internationally.
Show moreShow less
It offers knee, hip, and spinal and trauma replacement implants; and 3D-printed products, such as 3D-printed hip and knee replacement implants, 3D-printed spinal and trauma implants, as well as customized joint, pelvic, spinal and trauma implant products and customized value-added surgical services and orthopedic surgical robots.
The company also distributes third party orthopedic products; and offers surgical instruments and medical irrigators. Its principal customers include distributors, hospitals, physicians and surgeons, and patients.
The company was founded in 2003 and is based in Beijing, the People's Republic of China.
Stock analysis
AK Medical Holdings Ltd (1789) currently trades at HK$4.76, while our model-based Fair Value estimate is HK$7.71, implying the stock looks roughly 38% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$9.16 per share, and 20 of the 26 models we run sit above the HK$4.76 price.
Bear case: the Dividend Discount group reads lowest at HK$0.9750, and 6 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$4.72 (bear) to HK$10.68 (bull), the price of HK$4.76 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
AK Medical Holdings Ltd reported revenue of 1.5B CNY in FY2025 versus 761M CNY in FY2021, a compound +18.1%/yr. Reported net income was 339M CNY in FY2025, compounding +38.3%/yr from FY2021.
Key figures
Market cap HK$5.3B (≈ $675M) Small · P/E ratio 11.7 · P/S ratio 2.67 · Dividend yield 2.2% · Net margin 22.9% · Return on equity 13.7% · Return on assets (EBIT) 7.6% (5-year average) · Operating margin 28.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 76 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 62%, 1789 screens cheaper than that median.
Fair Value models
BearHK$4.72Fair Value HK$7.71BullHK$10.68
Price HK$4.76 · Upside +62.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+10.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
Start year 2020 (pandemic). Over 10 years: +21.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+20.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.2%
Dividend (yield on the price)2.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3.6% vs 16.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.37% → 25%
2025 sits 65% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −0.8% a year for the price and +7.8% for the forecasts.
Compare AK Medical Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 319 stocks
Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside+62.1% · Top 25%
Profitability
Return on equity (12 months)13.7% · Top 25%
Return on assets9.3% · Top 25%
Net margin (12 months)24.2% · Top 25%
Operating margin (12 months)28.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)10.2% · Above median
Dividend yield (12 months)2.2% · Above median
Balance sheet
Debt / equity0.00× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "AK Medical Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1789
Frequently asked questions
Is AK Medical Holdings Ltd (1789) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of HK$7.71 versus a price of HK$4.76, about +62% upside (undervalued).
What is the fair value of 1789?
Our model-based fair value for AK Medical Holdings Ltd is HK$7.71 (as of Nov 5, 2026), built from audited fundamentals. The current price: HK$4.76.
What is the quality score of 1789?
AK Medical Holdings Ltd has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AK Medical Holdings Ltd (1789)?
Our model-based price target is the fair value of HK$7.71 (as of Nov 5, 2026) from 26 valuation models. Cautious scenario HK$4.72, optimistic scenario HK$10.68. It is a calculation from audited fundamentals, not an analyst target.
What is the AK Medical Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$7.71, about +62% upside versus a price of HK$4.76 (undervalued). Cautious scenario HK$4.72, optimistic scenario HK$10.68. The calculation is refreshed regularly with new filings.
What is the revenue of AK Medical Holdings Ltd (1789)?
AK Medical Holdings Ltd reported trailing-twelve-month revenue of about 1.6B CNY (latest available figure, as of Nov 5, 2026).
Does AK Medical Holdings Ltd pay a dividend?
AK Medical Holdings Ltd currently shows a dividend yield of 2.23% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of AK Medical Holdings Ltd (1789) and when is the ex-dividend date?
AK Medical Holdings Ltd pays a dividend of HK$0.106 per share a year, a dividend yield of 2.2%. The last ex-dividend date was Jun 23, 2026. A dividend has been paid every year since at least 2018. The payout ratio is 28.1% of earnings. Free cash flow covers the dividend 3.32 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into AK Medical Holdings Ltd (1789)?
For today's price to be fair in a discounted-cash-flow model, AK Medical Holdings Ltd would have to grow free cash flow by +0.9 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.4 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 1789 use?
Our models discount AK Medical Holdings Ltd at 11.8 %: a base by market capitalisation (small), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AK Medical Holdings Ltd that is +0.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has AK Medical Holdings Ltd (1789) delivered so far?
Over the past 5 years revenue at AK Medical Holdings Ltd grew +7.4 % a year. The price currently implies free-cash-flow growth of +0.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AK Medical Holdings Ltd (1789) growing?
The median revenue growth in the sector is +6.3 % a year. That is the yardstick for the growth priced into AK Medical Holdings Ltd (+0.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AK Medical Holdings Ltd (1789)?
The free-cash-flow yield on the price is 7.02 %: that much free cash flow AK Medical Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AK Medical Holdings Ltd (1789)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AK Medical Holdings Ltd it is HK$7.71 per share (as of Nov 5, 2026), against a price of HK$4.76. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is AK Medical Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 1789 trades below its calculated fair value: price HK$4.76, fair value HK$7.71, a gap of about +62% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1789?
No. The price is what the market pays today (HK$4.76); the fair value is what the company's own numbers justify (HK$7.71). For AK Medical Holdings Ltd the two are HK$2.96 per share apart. That gap is exactly why we show both numbers side by side.
How much is AK Medical Holdings Ltd worth?
The market values AK Medical Holdings Ltd at about HK$5.3B (market capitalisation, as of Nov 5, 2026). Per share that is HK$4.76; our models calculate a fair value of HK$7.71 per share.
What do the bullish and bearish scenarios say about 1789?
Our models span a range for AK Medical Holdings Ltd: cautious scenario HK$4.72, base HK$7.71, optimistic HK$10.68 per share (as of Nov 5, 2026, price HK$4.76). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1789?
AK Medical Holdings Ltd trades at a price-to-earnings ratio of 11.7 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$7.71 is built from several models across several years. Other multiples: P/B 1.6, P/S 2.9, EV/EBITDA 8.1.
How solid is the balance sheet of AK Medical Holdings Ltd (1789)?
Balance-sheet figures for AK Medical Holdings Ltd (as of Nov 5, 2026): return on equity 13.7%, debt of 0.00 per unit of equity. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is 1789 from its 52-week high?
AK Medical Holdings Ltd trades at HK$4.76, about 32% below its 52-week high of HK$6.96 and 11% above the low of HK$4.29 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of HK$7.71 is for.
Which stocks are comparable to AK Medical Holdings Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AK Medical Holdings Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price HK$4.76, calculated fair value HK$7.71 (+62%), Quality Score 73/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1789 calculated?
We run AK Medical Holdings Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$7.71 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. AK Medical Holdings Ltd currently trades 38% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AK Medical Holdings Ltd (1789)?
The closing price on Nov 9, 2026 was HK$4.76. Our model-based fair value is HK$7.71, about +62% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AK Medical Holdings Ltd right now?
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (73/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$4.72 to HK$10.68) leaves room in how you read the outcome.
Where does the earnings growth of AK Medical Holdings Ltd (1789) come from?
Earnings per share at AK Medical Holdings Ltd grew +15.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +21.1 %, EBIT margin −5.0 %, tax rate +0.0 %, residual (interest, one-offs) +0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of AK Medical Holdings Ltd
How large is the market capitalisation of AK Medical Holdings Ltd (1789)?
The market capitalisation of AK Medical Holdings Ltd is HK$5.3B (≈ $675M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AK Medical Holdings Ltd (1789)?
The price-to-sales ratio of AK Medical Holdings Ltd is 2.67 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of AK Medical Holdings Ltd (1789)?
The dividend yield of AK Medical Holdings Ltd is 2.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of AK Medical Holdings Ltd (1789)?
The net margin of AK Medical Holdings Ltd is 22.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AK Medical Holdings Ltd (1789)?
The return on equity (ROE) of AK Medical Holdings Ltd is 13.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AK Medical Holdings Ltd (1789)?
On an EBIT basis the return on assets of AK Medical Holdings Ltd is 7.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AK Medical Holdings Ltd (1789)?
The operating margin of AK Medical Holdings Ltd is 28.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AK Medical Holdings Ltd (1789)?
Revenue at AK Medical Holdings Ltd is growing +10.2% versus a year earlier (3y avg +12.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at AK Medical Holdings Ltd (1789)?
Earnings per share at AK Medical Holdings Ltd are growing +26.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does AK Medical Holdings Ltd (1789) hold?
AK Medical Holdings Ltd holds more cash than debt, 230M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch AK Medical Holdings Ltd in the live analysis
One click puts AK Medical Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026